ApiJect has added product development capabilities, including Proof-of-Concept studies that use as little as 8 liters of vaccine or drug product to test compatibility in Blow-Fill-Seal (BFS) using ApiJect prefilled injector technology. Higher volumes may be needed based on the specific requirements of the drug product.
“We are delighted to make it easier than ever for pharmaceutical companies to test their drug product while realizing the benefits of the Prefilled ApiJect Injector,” said Bo Kowalczyk, Chief Commercial Officer, ApiJect. “With this added capability, biopharmaceutical development and manufacturing companies can provide us with a small amount of vaccine or drug product to test whether it can be reliably filled in BFS using ApiJect technology. We are excited to offer current and prospective customers Proof-of-Concept to “test drive” our technology.”
